Maurie Markman1. 1. University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, (Mail Box # 121), 77030, Houston, Texas 77030, USA. mmarkman@mdanderson.org
Abstract
PURPOSE: Optimal chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas remains undefined. Despite this fact, the selection of a cytotoxic anti-neoplastic drug regimen for an individual patient with this rare malignancy may substantially impact both short-term symptomatic improvement and overall quality-of-life, which includes the toxicity of therapy. PATIENTS AND METHODS: Two women with metastatic uterine carcinosarcomas recently treated at the Cleveland Clinic received therapy (carboplatin/paclitaxel) directly aimed at the "adenocarcinoma" component of their mixed endometrial cancers. RESULTS: Both patients achieved substantial short-term objective and subjective improvement in cancer-related signs and symptoms, while experiencing limited treatment-associated toxicities. CONCLUSION: This limited experience, and additional available data, suggest it is rational to initially treat patients with recurrent/metastatic uterine carcinosarcomas with anti-neoplastic drug strategies currently employed in the management of endometrial adenocarcinomas.
PURPOSE: Optimal chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas remains undefined. Despite this fact, the selection of a cytotoxic anti-neoplastic drug regimen for an individual patient with this rare malignancy may substantially impact both short-term symptomatic improvement and overall quality-of-life, which includes the toxicity of therapy. PATIENTS AND METHODS: Two women with metastatic uterine carcinosarcomas recently treated at the Cleveland Clinic received therapy (carboplatin/paclitaxel) directly aimed at the "adenocarcinoma" component of their mixed endometrial cancers. RESULTS: Both patients achieved substantial short-term objective and subjective improvement in cancer-related signs and symptoms, while experiencing limited treatment-associated toxicities. CONCLUSION: This limited experience, and additional available data, suggest it is rational to initially treat patients with recurrent/metastatic uterine carcinosarcomas with anti-neoplastic drug strategies currently employed in the management of endometrial adenocarcinomas.
Authors: M A Dimopoulos; C A Papadimitriou; V Georgoulias; L A Moulopoulos; G Aravantinos; D Gika; S Karpathios; S Stamatelopoulos Journal: Gynecol Oncol Date: 2000-07 Impact factor: 5.482
Authors: C F Levenback; G Tortolero-Luna; D K Pandey; A Malpica; V V Baker; L Whittaker; E Johnson; M Follen Mitchell Journal: Obstet Gynecol Clin North Am Date: 1996-06 Impact factor: 2.844
Authors: T W Burke; C A Stringer; M Morris; R S Freedman; D M Gershenson; J J Kavanagh; C L Edwards Journal: Gynecol Oncol Date: 1991-03 Impact factor: 5.482
Authors: G F Fleming; J M Fowler; S E Waggoner; L J Copeland; B E Greer; I Horowitz; G Sutton; R J Schilder; P M Fracasso; H G Ball; W P McGuire Journal: J Clin Oncol Date: 2001-02-15 Impact factor: 44.544
Authors: S G Silverberg; F J Major; J A Blessing; B Fetter; F B Askin; S Y Liao; A Miller Journal: Int J Gynecol Pathol Date: 1990 Impact factor: 2.762